Other Events ·
Silexion shareholders approve $515.9M authorized share capital and 1-for-24 reverse split
SLXNSilexion Therapeutics Corp
Shareholders approved a resolution to increase the company's authorized share capital by 500,000,000 ordinary shares, raising the total from 15,900,000 to 515,900,000 shares. The vote also passed a proposal for a reverse stock split on a 1-for-24 basis, consolidating existing shares into fewer shares with a par value of $3.24. These governance changes were ratified at an extraordinary general meeting held on October 26, 2026. Silexion Therapeutics Corp operates in the biotechnology industry.